Market Place
Sourcing Support
Cantargia Unveils AACR 2026 Presentation On Nadunolimab Study
19 Apr 2026 //
FIRSTWORD PHARMA
Nadunolimab Shows Anti-Tumor Data In Metastatic CRC
18 Mar 2026 //
PHARMIWEB
Cantargia Joins Van Lanschot Kempen`s Life Sciences Conference
05 Mar 2026 //
PHARMIWEB
Cantargia Doses First Patient in U.S. Colorectal Cancer Trial
23 Jan 2026 //
PHARMIWEB
Cantargia Provides Update On Overall Survival Data From TRIFOUR
05 Dec 2025 //
PHARMIWEB
Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer
02 Oct 2025 //
PHARMAWEB
Cantargia Strengthens Il1rap As Target In Pdac At AACR Conference
30 Sep 2025 //
PHARMAWEB
Cantargia Closes the Acquisition of CAN10 by Otsuka
11 Sep 2025 //
ACCESSWIRE
Cantargia Granted Important US Patent for Nadunolimab
29 Aug 2025 //
ACCESSWIRE
Cantargia`s Half-Year Report 2025 Published
21 Aug 2025 //
ACCESSWIRE
Otsuka inks $613M deal for Swedish Biotech`s IL1RAP Antibodies
17 Jul 2025 //
FIERCE BIOTECH
Cantargia Shares Nadunolimab Lung Cancer Combo Data
16 Jul 2025 //
ACCESSWIRE
Cantargia secures SEK 50M financing, extends cash runway to 2026
17 Jun 2025 //
ACCESSWIRE
Cantargia`s Nadunolimab Antibody Gets US FDA Fast Track Status
11 Jun 2025 //
ACCESSWIRE
Cantargia: Phase 1 Success, Subcutaneous CAN10 Dosing Confirmed
12 May 2025 //
ACCESSWIRE
Cantargia shows Nadunolimab reduces CIPN at AACR
25 Apr 2025 //
ACCESSWIRE
Cantargia Presents Preclinical Results on Anti-IL1RAP ADC at Canc
25 Apr 2025 //
ACCESSWIRE
Cantargia Reveals IL1RAP-Targeting ADC Results at AACR 2025
25 Mar 2025 //
ACCESSWIRE
Cantargia`s Abstract on Nadunolimab`s Anti-Tumor Activity
25 Mar 2025 //
ACCESSWIRE
Cantargia Publishes Strong Preclinical and Clinical Nadunolimab
18 Dec 2024 //
ACCESSWIRE
Cantargia Shows Nadunolimab Data In Triple Negative Breast Cancer
11 Dec 2024 //
ACCESSWIRE
Cantargia Presents on Nadunolimab With ADC at Oncology Conference
05 Nov 2024 //
ACCESSWIRE
Cantargia Reports Nadunolimab Results in Cancer Studies
28 Oct 2024 //
ACCESSWIRE
Cantargia Reports Results on Biomarkers and Safety in CAN10 Ph1 Study
11 Oct 2024 //
ACCESSWIRE
Cantargia`sPh 2 Nadunolimab Data Published In Cancer Research
10 Oct 2024 //
ACCESSWIRE
Cantargia Shows Nadunolimab Benefit After PD1-Inhibitor Relapse At ESMO
14 Sep 2024 //
ACCESSWIRE
Cantargia: New Data Support Nadunolimab Efficacy
08 Sep 2024 //
ACCESSWIRE
Cantargia presents Phase 2 Data in Pancreatic Cancer with Nadunolimab at ESMO
20 Jun 2024 //
ACCESSWIRE
Cantargia Presents Unique Effects of Nadunolimab in Pancreatic Cancer
08 Apr 2024 //
ACCESSWIRE
Cantargia Reports Progress Towards Start the Trial of Nadunolimab in Leukemia
27 Mar 2024 //
ACCESSWIRE
Cantargia Reports Regulatory Approval to Start Phase IIb Trial with Nadunolimab
20 Feb 2024 //
ACCESSWIRE
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy
12 Feb 2024 //
ACCESSWIRE
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab
24 Nov 2023 //
ACCESSWIRE
Cantargia to host R&D Day on results of nadunolimab in pancreatic cancer
04 Apr 2023 //
PR NEWSWIRE
Cantargia presents positive results for nadunolimab at AACR
14 Mar 2023 //
PR NEWSWIRE
Cantargia announces appointment of Patrik Renblad as Chief Financial Officer
01 Feb 2023 //
PR NEWSWIRE
